[1]
Mortazavi A, Mohammad S, Mortazavi J, Sihver L. Selective pressure-free treatments for COVID-19. Radiat 2021; 1(1): 18-32.
[2]
Pachetti M, Marini B, Benedetti F, et al. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. J Transl Med 2020; 18(1): 179.
[3]
Finkel Y, Mizrahi O, Nachshon A, et al. The coding capacity of SARS-CoV-2. Nature 2021; 589(7840): 125-30.
[4]
Chen L, Zhong L. Genomics functional analysis and drug screening of SARS-CoV-2. Genes Dis 2020; 7(4): 542-50.
[http://dx.doi.org/10.1016/j.gendis.2020.04.002] [PMID: 32363223]
[http://dx.doi.org/10.1016/j.gendis.2020.04.002] [PMID: 32363223]
[5]
Mittal A, Manjunath K, Ranjan RK, Kaushik S, Kumar S, Verma V. COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. PLoS Pathog 2020; 16(8): e1008762.
[6]
Cosar B, Karagulleoglu ZY, Unal S, et al. The most recent SARS-CoV-2 mutations and their subsequent viral variants. Cytokine Growth Factor Rev 2021.
[7]
Li X, Wang W, Zhao X, et al. Transmission dynamics and evolutionary history of 2019‐nCoV. J Med Virol 2020; 92(5): 501.
[8]
Collier DA, De Marco A, Ferreira IATM, et al. SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodies. medRxiv 2021; 2021.
[http://dx.doi.org/10.21203/RS.3.RS-156101/V1]
[http://dx.doi.org/10.21203/RS.3.RS-156101/V1]
[9]
Fikkert V, Cherepanov P, Van Laethem K, et al. ENV chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors. Antimicrob Agents Chemother 2002; 46(12): 3954-62.
[http://dx.doi.org/10.1128/AAC.46.12.3954-3962.2002] [PMID: 12435701]
[http://dx.doi.org/10.1128/AAC.46.12.3954-3962.2002] [PMID: 12435701]
[10]
Kupferschmidt K. The pandemic virus is slowly mutating. But does it matter? Science 2020; 369(6501): 238-9.
[11]
Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in COVID-19: Addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Target Ther 2020; 5(1): 1-10.
[12]
Oberemok VV, Laikova KV, Yurchenko KA. SARS-CoV-2 will continue to circulate in the human population: An opinion from the point of view of the virus-host relationship. Inflamm Res 2020; 69(7): 635-40.
[13]
Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev 2020; 7(6): 1012-23.
[http://dx.doi.org/10.1093/nsr/nwaa036] [PMID: 34676127]
[http://dx.doi.org/10.1093/nsr/nwaa036] [PMID: 34676127]
[14]
Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382(10): 929-36.
[15]
Lim J, Jeon S, Shin H-Y, et al. The author’s response: Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: The application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 2020; 35(7): e89.
[http://dx.doi.org/10.3346/jkms.2020.35.e89] [PMID: 32080993]
[http://dx.doi.org/10.3346/jkms.2020.35.e89] [PMID: 32080993]
[16]
Consortium WST. Repurposed antiviral drugs for COVID-19 - interim WHO solidarity trial results. N Engl J Med 2020; 384(4): 497-511.
[17]
Poudel S, Ishak A, Perez-Fernandez J, et al. Highly mutated SARS-CoV-2 Omicron variant sparks significant concern among global experts – What is known so far? Travel Med Infect Dis 2022; 45: 102234.
[18]
Science Brief: Omicron (B.1.1.529) Variant | CDC Available from: https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html Accessed on 2021 Dec 30.
[19]
Thakur V, Kanta Ratho R. OMICRON (B.1.1.529): A new SARS-CoV-2 variant of concern mounting worldwide fear. J Med Virol 2021.
[http://dx.doi.org/10.1002/jmv.27541]
[http://dx.doi.org/10.1002/jmv.27541]
[20]
Gerding DN. The search for good antimicrobial stewardship. Jt Comm J Qual Improv 2001; 27(8): 403-4.
[http://dx.doi.org/10.1016/S1070-3241(01)27034-5] [PMID: 11480201]
[http://dx.doi.org/10.1016/S1070-3241(01)27034-5] [PMID: 11480201]
[21]
Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29(6): 1109-15.
[http://dx.doi.org/10.1097/00003246-200106000-00003] [PMID: 11395584]
[http://dx.doi.org/10.1097/00003246-200106000-00003] [PMID: 11395584]
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Drug Targets
Current Neuropharmacology
Current Pharmaceutical Design
Current Pharmaceutical Analysis
Current Vascular Pharmacology
Letters in Drug Design & Discovery
Current Drug Discovery Technologies
Related Books
Frontiers in Drug Design and Discovery
New Findings from Natural Substances
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part II
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part I
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Pharmaceuticals for Targeting Coronaviruses
Frontiers in Cardiovascular Drug Discovery
Frontiers in Drug Design and Discovery
Medical Applications of Beta-Glucan
Article Metrics
5